Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance
Sign Up to like & getrecommendations! Published in 2019 at "Prostate Cancer and Prostatic Diseases"
DOI: 10.1038/s41391-019-0167-9
Abstract: Background We aimed to validate Decipher to predict adverse pathology (AP) at radical prostatectomy (RP) in men with National Comprehensive Cancer Network (NCCN) favorable-intermediate risk (F-IR) prostate cancer (PCa), and to better select F-IR candidates… read more here.
Keywords: risk; candidates active; intermediate risk; favorable intermediate ... See more keywords